Brukinsa front and center of BeiGene’s ASH offering

10 December 2024

BeiGene (Nasdaq: BGNE) has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition.

The orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK), Brukinsa (zanubrutinib), is front and center of the Sino-American company’s presentations at the congress.

Firstly, BeiGene presented five-year follow-up data from the SEQUOIA study which demonstrated treatment with Brukinsa reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology